Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okada, M.
Right arrow Articles by Mizutani, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okada, M.
Right arrow Articles by Mizutani, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 26:1088-1092, 2003
© 2003 by the American Diabetes Association, Inc.

Epidemiology/Health Services/Psychosocial Research
Original Article

Effects of Postmenopausal Hormone Replacement Therapy on HbA1c Levels

Mayumi Okada, MD1, Seiji Nomura, MD1, Yoko Ikoma, MD1, Eiko Yamamoto, MD1, Tomomi Ito, MD1, Takashi Mitsui, MD1, Koji Tamakoshi, MD2 and Shigehiko Mizutani, MD1

1 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 Nagoya University Graduate School of Medicine, Nagoya, Japan

OBJECTIVE—Estrogen seems to contribute to glucose homeostasis in women. The objective of this study was to examine the effects of hormone replacement therapy (HRT) on HbA1c levels in Japanese postmenopausal women and to determine whether the effects varied with age.

RESEARCH DESIGN AND METHODS—We studied 99 postmenopausal women taking HRT (mean ± SD age 56.5 ± 6.9 years, BMI 21.5 ± 2.3 kg/m2) and 101 postmenopausal women not on HRT (51.4 ± 6.1 years, 21.3 ± 2.4 kg/m2). HRT consisted of continuous conjugated equine estrogen (CEE; 0.625 mg/day) and medroxyprogesterone acetate (MPA; 2.5 mg/day) for >2 years.

RESULTS—HbA1c levels are positively associated with age and BMI in women who use HRT as well as in those who do not use HRT. After adjusting for age and BMI, HRT showed no effects on HbA1c levels. However, HbA1c levels were significantly lower in postmenopausal women aged 40–49 years who were taking HRT than in women of similar age who were not taking HRT (mean ± SE 4.776 ± 0.092 vs. 5.096 ± 0.078%, P < 0.05). No differences in HbA1c levels between women who did and did not use HRT were observed in those older than 50 years.

CONCLUSIONS—Oral HRT involving CEE combined with MPA may decrease HbA1c levels in women aged 40–49 years and is likely to have no adverse effects on HbA1c levels in women older than 50 years.

Abbreviations: CAD, coronary artery disease • CEE, conjugated equine estrogen • ERT, estrogen replacement therapy • HRT, hormone replacement therapy • MPA, medroxyprogesterone acetate • WHI, Women’s Health Initiative


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.